| Literature DB >> 33925008 |
Patricia Comella-Del-Barrio1, Bárbara Molina-Moya1, Jacqueline Gautier2, Raquel Villar-Hernández1, Mariette Jean Coute Doresca2, Beatriz Sallés-Mingels3, Lydia Canales-Aliaga4, Margareth Narcisse2, Tomás M Pérez-Porcuna4, Jacob Creswell5, Luis E Cuevas6, José Domínguez1.
Abstract
Current diagnostics for tuberculosis (TB) only manage to confirm a small proportion of children with TB and require respiratory samples, which are difficult to obtain. There is a need for non-invasive biomarker-based tests as an alternative to sputum testing. Fujifilm SILVAMP TB lipoarabinomannan (FujiLAM), a lateral-flow test to detect lipoarabinomannan in urine, is a novel non-sputum-based point-of-care diagnostic reported to have increased sensitivity for the diagnosis of TB among human immunodeficiency virus (HIV)-infected adults. We evaluate the performance of FujiLAM in children with presumptive TB. Fifty-nine children attending a paediatric hospital in Haiti with compatible signs and symptoms of TB were examined using Xpert MTB/RIF, smear microscopy and X-rays, and classified according to the certainty of diagnosis into bacteriologically confirmed TB (n = 5), unconfirmed TB (bacteriologically negative, n = 50) and unlikely TB (n = 4). Healthy children (n = 20) were enrolled as controls. FujiLAM sensitivity and specificity were 60% and 95% among children with confirmed TB. FujiLAM's high specificity and its characteristics as a point-of-care indicate the test has a good potential for the diagnosis of TB in children.Entities:
Keywords: LAM; children; diagnosis; lipoarabinomannan; point-of-care; tuberculosis; urine
Year: 2021 PMID: 33925008 DOI: 10.3390/jcm10091914
Source DB: PubMed Journal: J Clin Med ISSN: 2077-0383 Impact factor: 4.241